Starling Oncology (STLNW) Invested Capital (2020 - 2026)

Starling Oncology (STLNW) has reported Invested Capital for 7 consecutive years, with $55.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital fell 16.79% year-over-year to $55.0 million; the trailing twelve-month figure through Jun 2026 stood at $55.0 million (down 16.79% YoY), and the FY2025 full-year result was $61.7 million, down 36.23% from the prior year.
• Invested Capital slipped to $55.0 million in Q2 2026 per STLNW's latest filing, from $62.3 million in the prior quarter.
• Across five years, Invested Capital topped out at $207.0 million in Q3 2022 and bottomed at $55.0 million in Q2 2026.
• Historically, Invested Capital has averaged $119.8 million across 5 years, with a median of $121.6 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Invested Capital soared 95.32% in 2022, then plunged 44.58% in 2025.
• Over 5 years, Invested Capital stood at $203.8 million in 2022, then slipped by 29.41% to $143.9 million in 2023, then tumbled by 32.76% to $96.7 million in 2024, then sank by 36.23% to $61.7 million in 2025, then slipped by 10.91% to $55.0 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $55.0 million, $62.3 million, and $61.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.